Mindset Pharma Expands Benchmarking Data For First Generation Psychedelics Through The COPE Program With InterVivo Solutions
Mindset Pharma Inc. (Mindset), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, announced that, under its Co-operative Psychedelics Evaluation Platform (COPE) program with InterVivo Solutions (InterVivo), the Company has further developed its first generation psychedelics benchmarking data by establishing standard pharmacokinetic, brain penetration, and drug discrimination data and protocols across lysergic acid diethylamide (LSD), psilocybin, and o-methyl-bufotenin (5-MeO-DMT).
The COPE Program is a translational testing platform developed in cooperation with InterVivo to introduce an industry standard against . . .
